Ad
SGMO Quote Trading Chart Sangamo Therapeutics Inc.
home / stock / sgmo / sgmo quote
Quote | Sangamo Therapeutics Inc. (NASDAQ:SGMO)
| Last: | $2.05 |
|---|---|
| Change Percent: | -4.19% |
| Open: | $1.99 |
| Close: | $2.05 |
| High: | $2.175 |
| Low: | $1.93 |
| Volume: | 7,646,794 |
| Last Trade Date Time: | 12/13/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
SGMO Last Twenty Trading Days
| Last | Open | Close | High | Low | Volume | Date |
|---|---|---|---|---|---|---|
| $2.05 | $1.99 | $2.05 | $2.175 | $1.93 | 7,646,794 | 12-13-2024 |
| $1.91 | $1.9 | $1.91 | $1.93 | $1.8 | 4,482,848 | 12-12-2024 |
| $1.94 | $1.96 | $1.94 | $2.03 | $1.895 | 3,348,297 | 12-11-2024 |
| $1.95 | $2 | $1.95 | $2.0384 | $1.87 | 5,128,911 | 12-10-2024 |
| $2 | $2.02 | $2 | $2.05 | $1.93 | 3,750,915 | 12-09-2024 |
| $2.01 | $2 | $2.01 | $2.08 | $1.92 | 4,220,954 | 12-06-2024 |
| $1.97 | $1.95 | $1.97 | $1.99 | $1.8 | 4,576,717 | 12-05-2024 |
| $1.94 | $2.21 | $1.94 | $2.21 | $1.93 | 6,134,787 | 12-04-2024 |
| $2.15 | $2.37 | $2.15 | $2.37 | $2.07 | 4,663,771 | 12-03-2024 |
| $2.36 | $2.27 | $2.36 | $2.37 | $2.15 | 3,551,013 | 12-02-2024 |
| $2.26 | $2.3 | $2.26 | $2.38 | $2.14 | 3,004,315 | 11-29-2024 |
| $2.3 | $2.14 | $2.3 | $2.33 | $2.09 | 5,157,035 | 11-28-2024 |
| $2.3 | $2.14 | $2.3 | $2.33 | $2.09 | 5,157,035 | 11-27-2024 |
| $2.14 | $1.99 | $2.14 | $2.27 | $1.93 | 8,343,055 | 11-26-2024 |
| $1.94 | $1.9 | $1.94 | $1.95 | $1.79 | 5,194,677 | 11-25-2024 |
| $1.88 | $1.94 | $1.88 | $2 | $1.855 | 5,345,239 | 11-22-2024 |
| $1.96 | $1.95 | $1.96 | $2.03 | $1.89 | 3,300,531 | 11-21-2024 |
| $1.95 | $2.06 | $1.95 | $2.11 | $1.89 | 6,710,932 | 11-20-2024 |
| $1.96 | $1.88 | $1.96 | $2.03 | $1.845 | 6,410,576 | 11-19-2024 |
| $1.9 | $2.07 | $1.9 | $2.17 | $1.82 | 6,611,344 | 11-18-2024 |
News, Short Squeeze, Breakout and More Instantly...
Sangamo Therapeutics Inc. Company Name:
SGMO Stock Symbol:
NASDAQ Market:
Sangamo Therapeutics Inc. Website:
Ad
-
Sangamo plans to initiate enrollment of patients in the Phase 1/2 study for ST-503 in mid-2025 Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND)...
-
Announced clear regulatory pathway to Accelerated Approval from U.S. Food and Drug Administration (FDA) for isaralgagene civaparvovec in Fabry disease, using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potent...
-
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its third quarter 2024 financial results after the market close on Tuesday, November 12, 2024. The company will hold a conference call at 4:30 p.m. Eastern on T...